Discovery Europe 2024
22 - 23 May 2024 | Basel, Switzerland
Together with Neuroscience Drug Development Europe, attendees especially benefit from a 2-day event addressing emerging strategies for the drug development of neuroscience.
Explore Discovery Europe 2024: Unlocking Future Insights in Advancing Drug Discovery Pipelines & Research
Discovery Europe 2024 features the co-location of 22nd Annual Drug Discovery Summit & Discovery Chemistry Europe and the 5th Annual Neuroscience Drug Development Europe Congresses.
Join and network with over 350 industry discovery biology and chemistry leaders at the renowned Drug Discovery Summit in Basel, where they address critical strategies in target identification, validation and HIT optimisation of small and large molecule drugs. The Drug Design & Medicinal Chemistry focused event also offer insightful innovations in Automation And Synthesis In Organic Chemistry as well as Molecular Drug Design.
Together with Neuroscience Drug Development Europe, attendees especially benefit from a 2-day event addressing emerging strategies for the drug development of neuroscience and successful approaches for more targeted, precise, and transformative therapies to neurodegenerative diseases.
22nd Annual Drug Discovery Summit & Discovery Chemistry Europe Congress
Join and network with over 230 industry leaders at the renowned Drug Discovery Summit in Basel, where we will address the latest advancements in target identification, validation and HIT optimisation. The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics - based discovery, Organ-on-a-chip and 3D modelling. Learn about key focus areas in drug design including AI in drug design: in chemical synthesis, target ID capabilities & lead identification/optimisation.
- The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling.
- Learn about key focus areas in drug design including AI in drug design: in chemical synthesis, target ID capabilities & lead identification/optimisation.
- Join our 2-day innovation showcase situated alongside the main programme, which aims to inspire growth and create collaboration opportunities for all who attend.
Agenda at a Glance
- Workshop 1: Organ Modelling
- Workshop 2: Targeted Protein Degradation
- Workshop 3: Automation or AI in Medicinal Chemistry and Drug Design
Drug Discovery Summit
- Day One | Track 1: Identification And Validation Of Novel Targets For Next Generation Therapeutics
- Day One | Track 2: Animal And Disease Modelling, Organoid And Organ On The Chip Based Discovery
- Day One | Track 3: Discovery on Target – Screening and Genomic Strategies
- Day Two | Track 1: Phenotypic & Target Based Discovery Approaches
Drug Design & Medicinal Chemistry Summit
- Day One | Track 1: Computational Drug Design: AI In Chemical Synthesis, Target ID Capabilities, Lead Identification, Lead Optimisation, Measuring PK/PD & Prediction
- Day Two | Track 2: Hit Finding Technologies And Advancements
- Day Two | Track 3, Part 1: Automation And Synthesis In Organic Chemistry
- Day Two | Track 3, Part 2: Molecular Drug Design And Med Chem: Innovations In Fragment & Structured Based Drug Discovery
5th Annual Neuroscience Drug Development Europe Congress
A thorough, 2-day event addressing emerging strategies for the drug development of neuroscience and successful approaches for more targeted, precise, and transformative therapies to neurodegenerative diseases.
- Examine the latest advancements and emerging trends in developing neurological treatments, including targeted approaches and novel strategies.
- Discuss the pioneering innovations in stem cell technologies, with the latest updates on iPS cells for disease modelling and drug discovery.
- Establish in-depth knowledge of cutting-edge recent advances in gene therapy for CNS drug discovery and current opportunities for digital biomarkers in neuroscience.
Agenda at a Glance
Day One | Track 1: Therapeutic Strategies, Enabling Technologies & Biomarker Development
Day Two | Track 1: Drug Discovery For Neurodegenerative Disease
3rd Annual SmartLabs Automation & Robotics Congress
Explore Automate Europe 2024: Unlocking Future Insights in Automation & Robotics Research and Development
Automate 2024 consists of the 3rd Annual SmartLabs Automation & Robotics Congress, at which visionary leaders will discuss the current state of the industry, market trends and future growth areas pushing the pharma automation industry in the future. Join leaders, experts and researchers and discuss digital QA/QC labs, accelerating digital transformation, lab robotics & tools for drug discovery workflows, robotic process automation and implementing AI/ML in the lab. Automation of pharma manufacturing and the application of mobile robotics in QA/QC labs will also be discussed.
- The 2-day programme features the innovation and advancement in mobile robot technology and applications, and competitive advantages that can be gained in drug development and pharma manufacturing, automation and logistics.
- Learn about key focus areas in developments in the automation & digitisation of QA/QC labs, accelerating digital transformation, lab robotics & tools for drug discovery workflows, robotic, process automation and implementing AI/ML in the lab.
Agenda at a Glance
- Day One | Track 1: Bridging The Gap Between Automation & Digitalisation through FAIR & Digital Transformation
- Day One | Track 2: Smart Manufacturing & Digitisation Optimisation
- Day One | Track 3: Mobile Robotics In R&D Laboratories
- Day Two | Track 1: Automation with AI/ML & Robotics Tools in Drug Discovery & Development
- Day Two | Track 2: Data-Driven Modelling & Data Analytics for Drug Discovery & Development
Good number of 1-1 meetings with relevant people. Very happy with the networking process and the Oxford Global team are very nice and service minded.
Regional Sales Director
AxionBio
Absolutely outstanding conference attracting large pharma and aspiring biotechs. Oxford Global are excellent, the food is outstanding and the preset meetings are informal and impactful
Vice President of Business Development
Arctoris
The organisation was perfect. Good mix between excellent scientific presentations and network opportunities.
Pharmacology Associate Director
Novalix
This was my first time at the conference and it was a great experience. Very well organized conference and I learned a lot and made valuable connection - Thank you Oxford Global.
Senior Principal Scientist
Novartis
Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences
-
Over 100 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
-
Global Technological Showcase
An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field. -
Networking Emphasis
Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections -
Innovative Poster Displays
Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions
Companies Represented Include
Inspiring Tomorrow's Breakthroughs: Unleashing Innovation & Collaboration in Discovery Research & Development
Join engaging presentations featured in our innovation and collaboration track running across day 2 and 3, inspiring growth and creating space for collaboration opportunities for all who attend. The core attendee mix includes early-stage and emerging biotech or (academic) spinoff companies developing their own platforms or technologies with fewer than 30 employees.
The Innovation & Collaboration track will be comprising of 10-minute presentations and focused panel discussion sessions, encouraging networking, facilitating collaborations & showcasing emerging innovations in biomarkers discovery & development.
Featuring Attendees from Biotech and/or (Academic) Spinoff Companies Interested In:
- Seeking collaboration partners with pharma and solution providers
- Discovering new investment opportunities with pharma
- Learning about the latest industry trends & challenges
- Keeping updated with new innovations and technology solutions
- Showcasing their company profile to a targeted and engaged audience
The Discovery Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.
Please submit your poster presentation by no later than 20th December 2024 in the below category:
- Emerging Technologies
- Biomarkers in Therapeutics
- Biomarkers in Diagnostics
- Biomarkers in Clinical Trials & Precision Medicine
- Omics-Based Biomarker Discovery
- Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
- Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 20th December 2024
- ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA
Applicants must follow the procedure as follows:
- Register and submit an abstract by 20th December 2024 using the registration link to the left on this page
- Once registered you will be provided with the online abstract submission form
- Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.)
- The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event
- The winners’ 10-minute oral presentations will take place during the networking drinks on day 2
The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the Biomarkers series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.
The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights.
For further information contact help@oxfordglobal.com
Meet Our Expert Speakers
Discovery Europe 2024 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.
Below are some of our featured speakers:
All Speakers
Meet Our Esteemed Sponsors
Gold Sponsors
bit.bio's opti-ox™ precision cell programming technology enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step, at industrial scale, while maintaining exceptional purity and consistency.
bit.bio’s cell therapy pipeline, based on txCellsTM, is focused on serious diseases that lack effective treatments. The lead candidate, bbHEP01 based on txHepatocytes, is in development as a treatment for patients suffering from acute liver failure and acute-on-chronic liver failure.
The ioCells™ research cell product portfolio is opening up new possibilities for studying human biology and developing new medicines in research and drug discovery.
Silver Sponsors
Bronze Sponsors
Beyond binding & functional GPCR screening, EuroscreenFast also boasts an impressive deorphanisation track record with the identification of 17 natural receptor-ligand pairs. Resulting in 12 patents, this world leading platform is based on a unique collection of natural tissue extracts, a large library of cellular tools and more than three decades in the field. The company has one of the largest libraries of orphan GPCR cell lines, verified for receptor expression.
Custom cell line and assay development is also core to the offering at EuroscreenFast. Using a proprietary high-copy, bicistronic expression vector, cell lines from a range of species can be engineered to express the client’s target of choice and validated for use in functional or binding assays, or as a screening tool for drug discovery. EuroscreenFast has also developed specialized assays to bridge the gap between in vitro and in vivo data.
The team of highly skilled and expert scientists strategically design each program based on the latest knowledge of the target’s biology – EuroscreenFast is your unrivalled GPCR development partner.
EuroscreenFast is a business unit of EPICS Therapeutics SA.
Network & Programme Sponsors
For more information log on to: https://www.aurigeneservices.com/ or email us at: ContactAPSL@aurigeneservices.com
From early concept evaluation to transformative drug discovery campaigns, we solve your scientific challenges through innovative approaches for in vitro research.
• Obtain new insights into disease biology
• Accelerate the R&D process and reduce time-to-decision making
• Identify targets and lead compounds with potential to produce first-in-class medicines
Our unique discovery platform combines drug discovery expertise and disease area knowledge with cutting-edge technologies. With the platform, we are creating complex disease models and assays for functional and morphological screening.
We have established service modules in the areas of Peripheral Neuropathies, Neurodegeneration, Neuroplasticity and Neuroinflammation. Through our services, we can accelerate your target and lead discovery programs.
With over 3000 employees across facilities in India, UK and USA, it supports innovators across the entire drug discovery journey from concept to commercialisation, including exploratory biology, creative chemistry, DMPK, toxicology, developability & formulations, early phase development, process & analytical development, scale-up, tech transfer, clinical supplies and cGMP manufacturing.
Sai builds lasting partnerships with its clients through collaboration. Today, it serves 300+ companies, spanning start-ups, small & mid-sized pharma, and large pharma across US, UK, EU and Japan and count among its clients 17 of the top 20 large pharma companies by market capitalization.
Sai’s Discovery services are designed to accelerate the journey from ‘Concept to Clinic’ through speed & high-quality data by bringing together Medicinal Chemistry, Biology, DMPK, Toxicology under one roof to fast-track the DMTA (Design, Make, Test and Analyze) cycle. The company’s global delivery model delivers unique value to its customers through an optimal blend of talent, speed, and cost efficiency. The company has completed over 200 Discovery programs across Oncology, CNS, Inflammation, Antivirals, Rare diseases, and more.
Selvita provides comprehensive solutions supporting Clients and their drug discovery projects, across a broad range of therapeutic areas, specializing in infectious diseases, inflammation, fibrosis, and oncology. The Company offers a range of stand-alone or fully integrated drug discovery and development solutions spanning the entire value chain from early drug discovery to preclinical development, both for small molecules and therapeutic antibodies. On top of that, Selvita also offers analytical support for drug development and contract testing studies.
Selvita, established in 2007, operates globally with over 900 highly qualified employees, of which over 40% hold a PhD degree. The Company's research sites are in Krakow (HQ), Poznan and Wroclaw Poland, and Zagreb, Croatia. The international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK. Selvita is listed on the Warsaw Stock Exchange (WSE: SLV). For more information, please see www.selvita.com.
ADME/tox and PK profiling is delivered by our dedicated Admescope platform, biochemical and cellular assays, including cancer cell line screening by our Oncolines in vitro oncology platform.
We can support hit finding via HTS with our proprietary "SymeGold" library, but also fragment-based approaches;virtual screening;scaffold hopping and other techniques. A particular strength of ours lies in the transition from research to development with our large expert team providing creative route scouting and Process R&D solutions, leading to an efficient and fit for purpose GMP API production for clinical Phase 1 and Phase II studies. This includes formulation development and solid-form drug product supply for tox and Phase I studies.
Synthesis of challenging compounds such as macrocycles, chiral compounds, lipids, complex carbohydrates, ADCs, degraders, isotopically labelled compounds is in the DNA of Symeres with decades of experience.
We have been key to our partners' success for over 30 years. We bring deep scientific knowledge and creativity to your project goals. We make your molecules matter.
Interested in Sponsoring?
Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.
Learn moreLatest Resources
New Trailblazer Profluent Launches its AI-enabled OpenCRISPR-1 to Edit the Human Genome
Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments
From Screening to Success: How Molecular 'Super-Glue' SJ3149, Could Advance Cancer Treatments
Novo Nordisk Foundation and NVIDIA to Launch a State-of-the-Art National AI Research Centre
AI-driven High Throughput Screening for Targeted Drug Discovery
Post-Event Proceedings – Discovery Europe 2023
By Rail
Basel is an international rail hub with direct ICE, IC and EC connections to Germany, Austria, Italy, France and the Benelux countries. Messe Basel can be reached in five to ten minutes from the three railway stations in Basel: SBB (Switzerland), SNCF (France) (Frankreich) and DB (Badischer Bahnhof, Germany)
By Tram
From the SBB/SNCF railway station, it’s a ten-minute journey on the No. 1 or 2 Tram to the “Messeplatz/Exhibition Square” stop where Messe Basel and the Congress Center are located. From Badischer Bahnhof railway station, “Messeplatz/Exhibition Square” is the second stop on the No. 2 or 6 tram.
By Air
EuroAirport Basel-Mulhouse-Freiburg is 15 minutes by car from Messe Basel. Basel municipal transport’s No. 50 bus additionally provides a straightforward connection from the airport to the SBB/SNCF railway station. From there, tram No. 1 or 2 will take you directly to Messeplatz/Exhibition Square. From Zurich Airport a direct rail connection will bring you to the SBB/SNCF railway station in Basel in less than an hour. For further information including a map and full directions, please visit: https://www.messe-basel.com/en/about-us/getting-to-messe-basel/
By Car
Basel is located at the point where the Swiss, German and French motorway networks all meet. The exhibition and congress site has its own direct link to the A2 motorway. The “Messe” exit will take you straight to the Messe Basel car park with its 1,200 parking spaces.
We have sold out of our contracted bedrooms for this event. Please see nearby accommodation options for rates and availability here.
We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.
As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.
Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.
Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.
If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Discovery Europe 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.
Register Your Interest
Submit your details and a member of our team will be in touch